Xiaojiaoyang Li is a Professor and doctoral supervisor at Beijing University of Chinese Medicine (BUCM), where she also serves as a postdoctoral mentor. She completed postdoctoral training and was a senior visiting scholar at Virginia Commonwealth University, USA. She currently holds the positions of Deputy Director of the BUCM Research Office and Deputy Secretary-General of the Science and Technology Association of BUCM. Her research focuses on the pathogenesis of chronic liver disease and translational drug discovery within the framework of integrated traditional Chinese and Western medicine. Drawing on the "multi-component, multi-target and multi-effect" profile of traditional Chinese medicine, she has elucidated the mechanistic underpinnings of "multi-target interaction, multi-cell communication and multi-organ crosstalk" in the treatment of liver fibrosis and other chronic liver diseases.
Xiaojiaoyang Li is a Professor and doctoral supervisor at Beijing University of Chinese Medicine (BUCM), where she also serves as a postdoctoral mentor. She completed postdoctoral training and was a senior visiting scholar at Virginia Commonwealth University, USA. She currently holds the positions of Deputy Director of the BUCM Research Office and Deputy Secretary-General of the Science and Technology Association of BUCM. Her research focuses on the pathogenesis of chronic liver disease and translational drug discovery within the framework of integrated traditional Chinese and Western medicine. Drawing on the "multi-component, multi-target and multi-effect" profile of traditional Chinese medicine, she has elucidated the mechanistic underpinnings of "multi-target interaction, multi-cell communication and multi-organ crosstalk" in the treatment of liver fibrosis and other chronic liver diseases.